|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC13A5 |
Gene summary for SLC13A5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC13A5 | Gene ID | 284111 |
| Gene name | solute carrier family 13 member 5 | |
| Gene Alias | DEE25 | |
| Cytomap | 17p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q68D44 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 284111 | SLC13A5 | NAFLD1 | Human | Liver | NAFLD | 4.19e-11 | 9.97e-01 | -0.04 |
| 284111 | SLC13A5 | S41 | Human | Liver | Cirrhotic | 1.74e-05 | 7.18e-01 | -0.0343 |
| 284111 | SLC13A5 | S43 | Human | Liver | Cirrhotic | 2.40e-04 | -1.60e-01 | -0.0187 |
| 284111 | SLC13A5 | HCC1_Meng | Human | Liver | HCC | 2.22e-07 | -2.47e-01 | 0.0246 |
| 284111 | SLC13A5 | HCC2_Meng | Human | Liver | HCC | 2.81e-27 | 5.54e-02 | 0.0107 |
| 284111 | SLC13A5 | cirrhotic1 | Human | Liver | Cirrhotic | 9.56e-07 | -2.36e-01 | 0.0202 |
| 284111 | SLC13A5 | cirrhotic2 | Human | Liver | Cirrhotic | 3.40e-05 | -2.35e-01 | 0.0201 |
| 284111 | SLC13A5 | HCC1 | Human | Liver | HCC | 2.46e-21 | 4.84e+00 | 0.5336 |
| 284111 | SLC13A5 | Pt13.a | Human | Liver | HCC | 3.92e-02 | -2.12e-01 | 0.021 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00100387 | Liver | NAFLD | response to metal ion | 62/1882 | 373/18723 | 5.05e-05 | 1.19e-03 | 62 |
| GO:001003812 | Liver | Cirrhotic | response to metal ion | 150/4634 | 373/18723 | 2.27e-11 | 1.37e-09 | 150 |
| GO:00712487 | Liver | Cirrhotic | cellular response to metal ion | 73/4634 | 197/18723 | 7.73e-05 | 8.54e-04 | 73 |
| GO:00712417 | Liver | Cirrhotic | cellular response to inorganic substance | 81/4634 | 226/18723 | 1.21e-04 | 1.20e-03 | 81 |
| GO:001003822 | Liver | HCC | response to metal ion | 208/7958 | 373/18723 | 1.35e-07 | 2.56e-06 | 208 |
| GO:007124112 | Liver | HCC | cellular response to inorganic substance | 119/7958 | 226/18723 | 1.26e-03 | 6.92e-03 | 119 |
| GO:007124812 | Liver | HCC | cellular response to metal ion | 101/7958 | 197/18723 | 7.82e-03 | 3.10e-02 | 101 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC13A5 | SNV | Missense_Mutation | rs201674669 | c.664N>A | p.Ala222Thr | p.A222T | Q86YT5 | protein_coding | deleterious(0.04) | probably_damaging(0.995) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| SLC13A5 | SNV | Missense_Mutation | rs764711084 | c.441N>A | p.Met147Ile | p.M147I | Q86YT5 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-BH-A28O-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
| SLC13A5 | SNV | Missense_Mutation | novel | c.58A>C | p.Thr20Pro | p.T20P | Q86YT5 | protein_coding | deleterious(0.01) | possibly_damaging(0.743) | TCGA-E9-A22A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| SLC13A5 | SNV | Missense_Mutation | novel | c.1367N>C | p.Val456Ala | p.V456A | Q86YT5 | protein_coding | deleterious(0) | possibly_damaging(0.472) | TCGA-E9-A5FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SLC13A5 | insertion | Frame_Shift_Ins | novel | c.1505_1506insT | p.Met503HisfsTer22 | p.M503Hfs*22 | Q86YT5 | protein_coding | TCGA-B6-A0X5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| SLC13A5 | SNV | Missense_Mutation | c.796N>A | p.Leu266Met | p.L266M | Q86YT5 | protein_coding | deleterious(0.03) | benign(0.089) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| SLC13A5 | SNV | Missense_Mutation | rs587777577 | c.680N>T | p.Thr227Met | p.T227M | Q86YT5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLC13A5 | SNV | Missense_Mutation | c.1381N>C | p.Glu461Gln | p.E461Q | Q86YT5 | protein_coding | deleterious(0.02) | probably_damaging(0.98) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| SLC13A5 | SNV | Missense_Mutation | c.1699G>C | p.Glu567Gln | p.E567Q | Q86YT5 | protein_coding | tolerated(0.32) | benign(0.054) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SLC13A5 | SNV | Missense_Mutation | novel | c.1598A>G | p.Asn533Ser | p.N533S | Q86YT5 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-AA-3712-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |